# Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects

> **NCT01708590** · PHASE3 · TERMINATED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 661 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** 210 mg brodalumab
- **DRUG:** 140 mg brodalumab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01708590
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08
- **Primary completion:** 2014-05
- **Final completion:** 2015-08
- **Target enrollment:** 661 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2020-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01708590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01708590, "Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01708590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*